Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
Article in Frontiers in Public Health (March 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Article in Frontiers in Public Health (March 2024)
Article in Expert Review of Pharmacoeconomics & Outcomes Research (November 2023)
Article in PLOS ONE (October 2023)